Unknown

Dataset Information

0

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells.


ABSTRACT: NK cell adoptive therapy is a promising cancer therapeutic approach, but there are significant challenges that limiting its feasibility and clinical efficacy. One difficulty is the paucity of clinical grade manufacturing platforms to support the large scale expansion of highly active NK cells. We created an NK cell feeder cell line termed 'NKF' through overexpressing membrane bound IL-21 that is capable of inducing robust and sustained proliferation (>10,000-fold expansion at 5 weeks) of highly cytotoxic NK cells. The expanded NK cells exhibit increased cytotoxic function against a panel of blood cancer and solid tumor cells as compared to IL-2-activated non-expanded NK cells. The NKF-expanded NK cells also demonstrate efficacy in mouse models of human sarcoma and T cell leukemia. Mechanistic studies revealed that membrane-bound IL-21 leads to an activation of a STAT3/c-Myc pathway and increased NK cell metabolism with a shift towards aerobic glycolysis. The NKF feeder cell line is a promising new platform that enables the large scale proliferation of highly active NK cells in support of large scale third party NK cell clinical studies that have been recently intiatied. These results also provide mechanistic insights into how membrane-bound IL-21 regulates NK cell expansion.

SUBMITTER: Ojo EO 

PROVIDER: S-EPMC6797802 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells.

Ojo Evelyn O EO   Sharma Ashish Arunkumar AA   Liu Ruifu R   Moreton Stephen S   Checkley-Luttge Mary-Ann MA   Gupta Kalpana K   Lee Grace G   Lee Dean A DA   Otegbeye Folashade F   Sekaly Rafick-Pierre RP   de Lima Marcos M   Wald David N DN  

Scientific reports 20191017 1


NK cell adoptive therapy is a promising cancer therapeutic approach, but there are significant challenges that limiting its feasibility and clinical efficacy. One difficulty is the paucity of clinical grade manufacturing platforms to support the large scale expansion of highly active NK cells. We created an NK cell feeder cell line termed 'NKF' through overexpressing membrane bound IL-21 that is capable of inducing robust and sustained proliferation (>10,000-fold expansion at 5 weeks) of highly  ...[more]

Similar Datasets

| S-EPMC6491902 | biostudies-literature
| S-EPMC5462891 | biostudies-literature
| S-EPMC3261192 | biostudies-literature
2019-03-30 | GSE129044 | GEO
2022-10-21 | GSE199391 | GEO
2020-08-07 | GSE155813 | GEO
| S-EPMC2890739 | biostudies-literature
| S-EPMC3396759 | biostudies-literature
| PRJNA655693 | ENA
| S-EPMC6172804 | biostudies-other